Brought to you by 
Series F generates $45mm for Chimerix
25 Feb 2011
Executive Summary
Antivirals developer Chimerix Inc. has raised $45mm in its Series F financing led by New Leaf Venture Partners, which was joined by fellow first-time backers Pappas Ventures and Morningside Group, and returning shareholders Canaan Partners, Sanderling Ventures, Alta Partners, Asset Management, and Frazier Healthcare Ventures. Funding from the round will support ongoing clinical development of Phase II CMX001 and Phase I CMX157. A member from New Leaf Ventures and Pappas Ventures will join Chimerix’s board.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
-
Drug Discovery Tools
- ADMET
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series F generates $45mm for Chimerix
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice